UBCS039, a newly synthesized pyrrolo[1,2-a] quinoxaline derivative, is the first synthetic activator and specific for SIRT6 deacetylase activity [29], which has been reported to trigger SIRT6-dependent autophagy in different types of human cancer cell lines [30], and to activate SIRT6 to shift the macrophages from M1 to M2 [31]. The gene discussed is SIRT6; the disease is cancer.